Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus

Sarfaraz Hasni, Sarthak Gupta, Michael A. Davis, Elaine Poncio, Yenealem Temesgen‐Oyelakin, Philip M. Carlucci, Xinghao Wang, Mohammad Naqi, Martin P. Playford, Rishi R. Goel, Xiaobai Li, Ann Biehl, Isabel Ochoa-Navas, Zerai Manna, Yinghui Shi, Donald E. Thomas, Jinguo Chen, Angélique Biancotto, Richard Apps, Foo Cheung, Yuri Kotliarov, Ashley L. Babyak, Huizhi Zhou, Rongye Shi, Katie Stagliano, Wanxia Li Tsai, Laura Vian, Nathalia Gazaniga, Valentina Giudice, Shajia Lu, Stephen R. Brooks, Meggan Mackay, Peter K. Gregersen, Nehal N. Mehta, Alan T. Remaley, Betty Diamond, John J. O’Shea, Massimo Gadina, Mariana J. KaplanNature Communications 2021 · DOI

TL;DR

This study investigated the safety and potential cardiovascular benefits of tofacitinib, a Janus kinase (JAK) inhibitor, in patients with mild-to-moderate systemic lupus erythematosus (SLE). The trial found tofacitinib to be safe and well-tolerated, and importantly, it improved key cardiometabolic and vascular markers associated with the increased cardiovascular risk seen in SLE patients.

What Problem Does This Paper Address?

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by a significantly increased risk of premature cardiovascular disease (CVD), even in younger individuals. This heightened risk is not fully explained by traditional CVD risk factors and is thought to be linked to chronic inflammation, immune dysregulation, and specific pathways like the type I interferon (IFN) system and neutrophil activity. Existing treatments have not effectively addressed this accelerated atherosclerosis. This paper explores whether tofacitinib, a JAK inhibitor known to modulate inflammatory pathways, could offer a therapeutic benefit by improving these cardiovascular risk factors in SLE patients.

Methods

This was a Phase 1, double-blind, randomized, placebo-controlled safety trial. Thirty SLE subjects with mild-to-moderate disease activity were randomized in a 2:1 ratio to receive either tofacitinib (5 mg twice daily) or a placebo for 8 weeks, followed by a 4-week follow-up period. The primary outcome was safety and tolerability. Secondary outcomes included clinical response and mechanistic studies, focusing on cardiometabolic parameters, immune markers, and vascular function.

Key techniques employed included:

  • Phosphoflow cytometry: To assess the phosphorylation of STAT proteins (STAT1, STAT3, STAT5), indicating JAK pathway activity.
  • Whole blood RNA sequencing (RNA-seq) and Nanostring: To analyze gene expression, specifically focusing on the type I IFN gene signature.
  • Flow cytometry: To quantify low-density granulocytes (LDGs).
  • ELISA and other assays: To measure levels of circulating neutrophil extracellular traps (NETs), high-density lipoprotein (HDL) cholesterol and particle number, lecithin: cholesterol acyltransferase (LCAT) concentration, and cholesterol efflux capacity.
  • Non-invasive vascular function studies: Including cardioankle vascular index (CAVI), pulse wave velocity (PWV), and reactive hyperemia index (RHI) to assess arterial stiffness and endothelial function.
  • Statistical analysis: Using mixed-effects models and ANCOVA to compare changes from baseline between treatment groups, with stratification by STAT4 risk allele status.

Datasets

Not discussed in the paper.

Key Insights and Ideas

  • JAK inhibition as a potential CVD intervention in SLE: The study provides early evidence that targeting the JAK-STAT pathway with tofacitinib may not only address SLE-related immune dysregulation but also directly improve cardiovascular risk factors.
  • STAT4 risk allele as a potential biomarker: The findings suggest that individuals with the STAT4 risk allele, known to be associated with more severe SLE and increased CVD risk, may experience more robust benefits from tofacitinib, particularly in terms of NET reduction and improvements in HDL function and arterial stiffness. This opens avenues for personalized medicine approaches.
  • Modulation of the IFN-neutrophil axis: Tofacitinib effectively reduced the type I IFN gene signature and modulated specific neutrophil populations (LDGs) and NET formation, which are implicated in SLE-associated vascular damage.
  • Impact on HDL metabolism: The drug significantly improved HDL cholesterol levels, particle number, and LCAT activity, suggesting a positive impact on reverse cholesterol transport, a key process in preventing atherosclerosis.

Key Results

  • Safety: Tofacitinib was found to be safe and well-tolerated in mild-to-moderate SLE patients, with no severe adverse events, opportunistic infections, or thromboembolic events reported.
  • Cardiometabolic improvements:
    • Significant increase in HDL-C levels (p = 0.0006, 95% CI: 4.12, 13.32).
  • Significant increase in HDL particle number (p = 0.0008, 95% CI: 1.58, 5.33).
  • Significant increase in LCAT concentration (p = 0.024, 95% CI: 1.1, -26.5).
  • A trend towards improved cholesterol efflux capacity (p = 0.08, 95% CI: -0.01, 0.24).
  • Vascular function improvements:
    • Improvements in arterial stiffness (CAVI, PWV) and endothelium-dependent vasorelaxation (RHI).
  • These improvements were more pronounced in subjects with the STAT4 risk allele.
  • Immunologic changes:
    • Significant decrease in the type I IFN gene signature.
  • Significant decrease in low-density granulocytes (LDGs).
  • Significant decrease in circulating NETs, particularly in STAT4 risk allele-positive subjects.
  • Inhibition of pSTAT1 in CD4+ T cells.

Limitations and Future Work

  • Small sample size and short duration: The study enrolled only 30 subjects for a relatively short treatment period (8 weeks). This limits the statistical power to detect smaller effects and assess long-term efficacy or safety.
  • Exploratory nature: The study was a Phase 1 trial, and adjustments for multiple comparisons were not made, meaning some findings should be interpreted cautiously.
  • Mild-to-moderate disease: The results may not be generalizable to patients with more severe SLE.
  • No concomitant immunosuppressants: The safety profile in patients on other immunosuppressive therapies remains unknown.

Future work should focus on larger, longer-term trials to confirm these findings, assess the efficacy of tofacitinib in preventing CVD events in SLE, and further explore the role of the STAT4 risk allele in predicting treatment response. Investigating the precise mechanisms by which tofacitinib modulates neutrophil function and vascular parameters is also warranted.

Summary updated

Abstract

Increased risk of premature cardiovascular disease (CVD) is well recognized in systemic lupus erythematosus (SLE). Aberrant type I-Interferon (IFN)-neutrophil interactions contribute to this enhanced CVD risk. In lupus animal models, the Janus kinase (JAK) inhibitor tofacitinib improves clinical features, immune dysregulation and vascular dysfunction. We conducted a randomized, double-blind, placebo-controlled clinical trial of tofacitinib in SLE subjects (ClinicalTrials.gov NCT02535689). In this study, 30 subjects are randomized to tofacitinib (5 mg twice daily) or placebo in 2:1 block. The primary outcome of this study is safety and tolerability of tofacitinib. The secondary outcomes include clinical response and mechanistic studies. The tofacitinib is found to be safe in SLE meeting study's primary endpoint. We also show that tofacitinib improves cardiometabolic and immunologic parameters associated with the premature atherosclerosis in SLE. Tofacitinib improves high-density lipoprotein cholesterol levels (p = 0.0006, CI 95%: 4.12, 13.32) and particle number (p = 0.0008, CI 95%: 1.58, 5.33); lecithin: cholesterol acyltransferase concentration (p = 0.024, CI 95%: 1.1, -26.5), cholesterol efflux capacity (p = 0.08, CI 95%: -0.01, 0.24), improvements in arterial stiffness and endothelium-dependent vasorelaxation and decrease in type I IFN gene signature, low-density granulocytes and circulating NETs. Some of these improvements are more robust in subjects with STAT4 risk allele.
BibTeX
@inproceedings{hasni2021phase,
  author = {Sarfaraz Hasni and Sarthak Gupta and Michael A. Davis and Elaine Poncio and Yenealem Temesgen‐Oyelakin and Philip M. Carlucci and Xinghao Wang and Mohammad Naqi and Martin P. Playford and Rishi R. Goel and Xiaobai Li and Ann Biehl and Isabel Ochoa-Navas and Zerai Manna and Yinghui Shi and Donald E. Thomas and Jinguo Chen and Angélique Biancotto and Richard Apps and Foo Cheung and Yuri Kotliarov and Ashley L. Babyak and Huizhi Zhou and Rongye Shi and Katie Stagliano and Wanxia Li Tsai and Laura Vian and Nathalia Gazaniga and Valentina Giudice and Shajia Lu and Stephen R. Brooks and Meggan Mackay and Peter K. Gregersen and Nehal N. Mehta and Alan T. Remaley and Betty Diamond and John J. O’Shea and Massimo Gadina and Mariana J. Kaplan},
  title = {{Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus}},
  booktitle = {Nature Communications},
  year = {2021},
  doi = {10.1038/s41467-021-23361-z},
}
Figure